publication date: Oct 18, 2011
|
author/source: The Scott Partnership
Novozymes Biopharma, part of Novozymes
A/S, world leader in bioinnovation, will showcase its soon to be launched state
of the art Q7 cGMP-grade hyaluronic acid (HA) at CPhI Worldwide 2011. The new
Bacillus-derived HA has been developed
to improve how customers process and formulate HA for medical device and pharmaceutical
applications, helping to speed up product development and creating improved therapeutics.
The product confers a range of unique performance advantages for medical
devices, drug delivery and formulation and will be showcased on booth
#42H55
in hall
4.2 at the Messe Frankfurt, October 25-27, in Frankfurt,
Germany.
"Novozymes is delighted to be returning
to CPhI to showcase the company's soon to be launched Q7 cGMP HA", comments
Hans Ole Klingenberg, global marketing director at Novozymes. "Delegates will
be able to see the HA and our team of experts will be on hand to provide
insight into how it can be incorporated into their manufacturing processes to
reduce testing time, save on manufacturing costs and take products to market
faster."
Novozymes' HA has been developed to
expand opportunities for HA across multiple applications in the pharmaceutical
and medical device industries. Produced at Novozymes' new facility in Tianjin,
China, which has been designed exclusively for HA, the company uses a patented
water based process which is run in compliance with ICH Q7 cGMP guidelines. The
resulting HA is free of animal derived components and organic solvents, resulting
in a high degree of purity and reduced risk of contamination. It offers high batch-to-batch
consistency with tight control of molecular weight for improved formulation
control, as well as the capability to dissolve up to five times faster than
other commercially available sources of HA. In addition, superior heat
stability permits autoclaving without significant loss of product viscosity.
The new HA can be customized further using
Novozymes' proprietary crosslinking technology to achieve a specified
viscosity, allowing the product to be adapted for a range of drug delivery and
medical device applications. From ophthalmology and dermal filling to
osteoarthritis treatments and cancer treatment, the unique technology will
assist customers to create improved therapeutics with real benefits for both
manufacturers and patients.
Novozymes' HA will be commercially
available in December.
To learn more about Novozymes' HA, please
visit booth
#42H55 in hall
4.2 at CPhI Worldwide 2011.
Alternatively, please visit
www.biopharma.novozymes.com.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.